undamentalytics Newsletter
Sign in

Taysha Gene Therapies, Inc. income statement

In fiscal 2025, Taysha Gene Therapies, Inc. reported revenue of $9.8m, up 17.3% on the year before, operating income of −$110m (a -1130.6% margin) and net income of −$109m, or −$0.34 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3158105
Research and development91576686123
General and administrative3730293439
Operating income−162−72−91−110−153
Interest expense45000
Income tax00000
Net income−166−112−89−109−150
Diluted EPS−$3.78−$0.96−$0.36−$0.34−$0.41
Diluted shares (average)44m116m250m320m362m
EBITDA−161−71−90−109−152

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IMRN vs TSHAIVA vs TSHAANL vs TSHACGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Taysha Gene Therapies, Inc.